Indaptus Therapeutics, Inc.
INDP evidence brief
What we can confirm
- BioSniper Score:
- 6.4 / 10
- Market Cap:
- $369.1M
- Lead Asset:
- decoy20 (Phase 1/Phase 2)
What it means
What to watch
Prepared research question
What matters most for INDP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · INDP
Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company that has discontinued its lead Decoy20 clinical program and is evaluating strategic alternatives, including a potential acquisition or investment, while its cash runway extends through mid-2027.
Key risk: No active clinical programs
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 1 clinical trial for Indaptus Therapeutics, Inc..
Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company that has discontinued its lead Decoy20 clinical program and is evaluating strategic alternatives, including a potential acquisition or investment, while its cash runway extends through mid-2027.
- Indaptus has discontinued all active clinical development of its lead candidate Decoy20; no participants remain in any Decoy20 study as of mid-2026 [sec · filed 2026-08-17].
- Cash and cash equivalents were $7.6M as of June 30, 2026, with an additional $4.0M in certificates of deposit, providing liquidity through Q2 2027 [sec_mda · as of 2026-08-13].
- Net loss for the six months ended June 30, 2026 was approximately $1.8M, down from $5.4M in the prior-year period due to reduced operating expenses [latest reported financials (as of 2026-06-30)].
- The company is evaluating strategic alternatives for its Decoy20 program and broader operations, including potential investments, acquisitions, or other transactions [sec · filed 2026-08-17].
- A $12.0M private placement completed in Q2 2026 strengthened the balance sheet [sec_mda · as of 2026-08-13].
What works
- Cash runway extends through Q2 2027, providing time to evaluate strategic alternatives without near-term financing pressure [sec_mda · as of 2026-08-13].
- The Decoy20 platform is based on a patented, multi-targeted immunotherapy approach that could be revived if partnered or acquired [sec_mda · as of 2026-05-15].
- Operating expenses have been significantly reduced, narrowing net losses and preserving cash [sec_mda · as of 2026-08-13].
What to weigh
- All clinical development of Decoy20 has been discontinued, with no active programs or enrolled participants [sec · filed 2026-08-17].
- The company faces substantial uncertainty regarding its future direction and viability, as it has no ongoing clinical or development activities [sec · filed 2026-08-17].
- A strategic review may not result in a favorable transaction, and the company may be unable to resume development without additional financing [sec · filed 2026-06-26].
- Concentration of ownership among new significant stockholders could limit other stockholders' influence over major decisions [sec · filed 2026-06-26].
From the filings
Quoted directly from source documents.
Decoy20 clinical program has been discontinued
“the Company has discontinued further enrollment in the Combination Study, there are no participants remaining in any ongoing Decoy20 clinical study, and the Company does not have any active clinical development programs”
SEC filings · August 17, 2026
Cash position and runway
“cash and cash equivalents of approximately $7.6 million as of June 30, 2026, together with approximately $4.0 million held in certificates of deposit that are available for withdrawal will provide us with sufficient liquidity to fund our operating expenses and capital expenditure requirements through the second quarter of 2027”
SEC MD&A · August 13, 2026
Strategic alternatives being evaluated
“We are evaluating strategic alternatives for our Decoy20 program and broader business operations, which may include strategic transactions, research collaborations, investments in or acquisitions of other businesses, and other potential growth opportunities”
SEC filings · August 17, 2026
Net loss reduction
“net loss of approximately $5.4 million and the decrease in our accounts payable and other current liabilities of approximately $5.5 million”
SEC MD&A · August 13, 2026
Risks & what to watch (4)›
Key risks
- No active clinical programs — All Decoy20 studies are discontinued; no participants remain and no development is ongoing [sec · filed 2026-08-17].
- Strategic review outcome uncertain — The company may not find a suitable transaction or partner, leaving it without a viable path forward [sec · filed 2026-06-26].
- Cash runway limited to mid-2027 — Without additional financing or a transaction, liquidity may be insufficient beyond Q2 2027 [sec_mda · as of 2026-08-13].
- Concentrated stockholder control — New significant stockholders may exert substantial influence, potentially delaying or deterring favorable transactions [sec · filed 2026-06-26].
What to watch
- Outcome of the strategic review, including any potential acquisition, investment, or partnership [sec · filed 2026-08-17].
- Cash burn rate and any additional financing activities, given the runway through Q2 2027 [sec_mda · as of 2026-08-13].
- Any resumption of Decoy20 development or new pipeline initiatives if financing or a transaction is secured [sec · filed 2026-08-17].
- Changes in stockholder composition or control that could influence corporate decisions [sec · filed 2026-06-26].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run Indaptus Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Indaptus Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.05 · 0% dilution
Lead: Phase 1/Phase 2
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
6
Total value held
$129K
| Holder | Shares | Value |
|---|---|---|
| citadel advisors llc | 39,018 | $71K |
| geode capital management, llc | 27,007 | $49K |
| morgan stanley | 2,697 | $5K |
| tower research capital llc (trc) | 1,890 | $3K |
| sbi securities co., ltd. | 17 | $31 |
| cwm, llc | 2 | $4 |
Short Interest
as of Apr 30, 2026- % of float
- 8.3%
- Days to cover
- 0.9
- Shares short
- 52,565
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
INDP short interestGovernance
Frequently asked questions
What is the AI investment thesis for Indaptus Therapeutics, Inc.?
Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company that has discontinued its lead Decoy20 clinical program and is evaluating strategic alternatives, including a potential acquisition or investment, while its cash runway extends through mid-2027.
What is Indaptus Therapeutics, Inc.'s lead drug candidate?
Indaptus Therapeutics, Inc.'s most advanced tracked candidate is decoy20 (Phase 1/Phase 2) for Solid Tumor, Adult.
Who is the CEO of Indaptus Therapeutics, Inc.?
Mr. Junyi Dai is the chief executive officer of Indaptus Therapeutics, Inc. (INDP).
Where is Indaptus Therapeutics, Inc. headquartered?
Indaptus Therapeutics, Inc. (INDP) is headquartered in New York, NY, United States.
What therapeutic areas does Indaptus Therapeutics, Inc. focus on?
Indaptus Therapeutics, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.